Tau and glial fibrillary acidic proteins should also undergo further evaluation as potential biomarkers and surrogate endpoints for clinical trials of therapeutic agents for ALSP. The gene discussed is GFAP; the disease is Hereditary diffuse leukoencephalopathy with axonal spheroids and pigmented glia.